The new COO at Hybrigenics has made a number of jumps in her career. Starting out in research, she headed to development and later moved again when an offer came along and piqued her curiosity about working on the business side. Now, she’s making the shift from big pharma to a small proteomics company. “It is indeed a major new challenge in my career,” says Anne-Fabienne Weitsch.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.